Abiopharma

🔍 Rosenbloom David S. (Executive)

Company: BAXTER INTERNATIONAL INC (BAX)

Report Date: 2026-02-09

Detailed Transactions and Holdings:

• Acquired 17,055 shares of Common Stock, $1 par value (Direct)
  Date: 2026-02-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 124,689.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 5,225 shares of Common Stock, $1 par value at $21.73 per share (Direct)
  Date: 2026-02-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 119,464.00 | transaction_form_type: 4 | Footnotes: F2, F3

Footnotes:

• F1: Represents shares awarded from the performance share unit award granted on March 1, 2023 pursuant to the Amended & Restated Baxter International Inc. 2021 Incentive Plan and the Annual Equity Program adopted by Baxter International Inc. (Baxter) (the 2023 PSUs). The award provided that one-third of the performance share units are awarded based on Baxter's Sales Compound Annual Growth Rate (Sales CAGR) performance, Baxter's Total Shareholder Return (TSR) performance, and Baxter's Total Return on Invested Capital (ROIC) performance over the three-year performance period January 1, 2023 to December 31, 2025 (the Three-Year Performance Period). These shares have vested as the Three-Year Performance Period has ended.
• F2: Represents the number of shares forfeited by the reporting person to cover the withholding of taxes incurred as a result of the vesting of the 2023 PSUs.
• F3: Total includes the automatic reinvestment of dividends.